Background: A continuum of non-suppressible aldosterone production has been demonstrated in normotensive individuals, termed subclinical primary aldosteronism (PA), and is consistently associated with increased risk for developing hypertension and cardiovascular disease. The hormonal mechanisms accounting for subclinical PA are not well understood.
Method: To quantify the magnitude of subclinical PA, prospectively recruited normotensive participants (n=75) had their maximally suppressed plasma aldosterone assessed after maintaining supine posture following an oral sodium loading protocol. To investigate the endocrine mechanisms involved with this continuum, multiple maneuvers were conducted to evaluate: 1) natriuretic peptide physiology (N-terminal pro B-type natriuretic peptide (NT-proBNP) suppression and stimulation using dietary sodium modulation), 2) Angiotensin II (AngII)-dependent aldosterone production (via dietary sodium restriction and via infusion of exogenous AngII), 3) AngII-independent aldosterone production (via saline suppression test [SST]) and 4) ACTH-mediated aldosterone production (via dexamethasone suppression test and ACTH-stimulation test).
Results: Greater magnitude of subclinical PA was associated with lower basal NTproBNP (p-trend <0.01) and blunted stimulation of NTproBNP following sodium loading (p-trend = 0.023). The magnitude of subclinical PA was also associated with greater AngII-dependent (p-trend <0.001) and AngII-independent (p-trend <0.001) aldosterone production, and paralleled the severity of ACTH-mediated aldosterone production (p-trends <0.001). Following SST, 24.2% of participants had a post-saline aldosterone greater than 10 ng/dL and 72.7% had a post-saline aldosterone greater than 6 ng/dL, confirming that the continuum of subclinical PA included overt PA pathophysiology within these normotensive participants.
Conclusion: These findings demonstrate that the pathophysiologic continuum of subclinical PA in normotensive people is characterized by natriuretic peptide insufficiency and heightened aldosterone responses to both AngII and ACTH. These early maladaptive hormonal changes provide mechanistic explanations for the role of subclinical PA in the pathogenesis of hypertension.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1210/clinem/dgaf129 | DOI Listing |
Crit Pathw Cardiol
March 2025
Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Hyperuricemia, characterized by elevated serum uric acid levels, has been linked to cardiovascular diseases such as hypertension, atrial fibrillation, chronic kidney disease, heart failure, metabolic syndrome, and coronary artery disease. This relationship, however, is complex; while some studies indicate a strong association, others suggest it may be influenced by confounding factors. The rising global prevalence of hyperuricemia underscores the necessity for a deeper understanding of its cardiovascular implications.
View Article and Find Full Text PDFActa Biochim Biophys Sin (Shanghai)
March 2025
Department of Cardiology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine. Shanghai 200025, China.
Hypoxia-induced apoptosis plays a critical role in the progression of various cardiac diseases, such as heart failure and acute myocardial infarction (AMI). Aldosterone reductase 1C3 (AKR1C3), a member of the aldo-keto reductase superfamily, participates in the metabolism of steroid hormones and redox reactions . Imbalances in prostaglandin levels have been linked to coronary events.
View Article and Find Full Text PDFJ Clin Endocrinol Metab
February 2025
Center for Adrenal Disorders, Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Background: A continuum of non-suppressible aldosterone production has been demonstrated in normotensive individuals, termed subclinical primary aldosteronism (PA), and is consistently associated with increased risk for developing hypertension and cardiovascular disease. The hormonal mechanisms accounting for subclinical PA are not well understood.
Method: To quantify the magnitude of subclinical PA, prospectively recruited normotensive participants (n=75) had their maximally suppressed plasma aldosterone assessed after maintaining supine posture following an oral sodium loading protocol.
Mol Biol Rep
March 2025
Programa de Pós-Graduação em Ciências Farmacêuticas (CiPharma), Escola de Farmácia, Universidade Federal de Ouro Preto, Ouro Preto, Brazil.
Background: The association of genetic variants and environmental factors contribute to increased susceptibility to arterial hypertension (AH). Polymorphisms of the angiotensin-converting enzyme (ACE) gene have been identified as a genetic risk factor related to blood pressure (BP) levels and liver function, since they influence the renin-angiotensin-aldosterone system (RAAS).
Objective: To evaluate the influence of the rs4344 polymorphism of the ACE gene on AH and biochemical parameters of liver function (ALT, AST, GGT and ALP) in normotensive and hypertensive patients.
Endocr Pract
February 2025
NHC Key Laboratory of Endocrinology, Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, 100730, China. Electronic address:
Objective: This study aimed to explore the non-invasive and accurate evaluation methods of primary aldosteronism (PA) classification.
Methods: There were 99 patients with aldosterone-producing adenoma (APA) and 61 with idiopathic hyperaldosteronism (IHA) recruited in this study. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) and Ga-pentixafor PET/CT were performed in this cohort.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!